Cargando…

Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction

OBJECTIVE: Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tunçez, Abdullah, Altunkeser, Bülent Behlül, Öztürk, Bahadır, Ateş, Muhammed Salih, Tezcan, Hüseyin, Aydoğan, Canan, Kırık, Emre Can, Yalçın, Muhammed Ulvi, Aygül, Nazif, Demir, Kenan, Akyürek, Fikret
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955059/ https://www.ncbi.nlm.nih.gov/pubmed/31674929 http://dx.doi.org/10.14744/AnatolJCardiol.2019.64249

Ejemplares similares

Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients
por: Tezcan, Hüseyin, et al.
Publicado: (2023)

The Prognostic Utility of Plasma NGAL Levels in ST Segment Elevation in Myocardial Infarction Patients
por: Avci, Ahmet, et al.
Publicado: (2020)

Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
por: Clearfield, Michael B, et al.
Publicado: (2006)

Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
por: Torimoto, Keiichi, et al.
Publicado: (2013)

Myocardial Blush Grade Predicts Postoperative Atrial Fibrillation following Mitral Valve Replacement: A Novel Perspective
por: Çiçek, Ömer Faruk, et al.
Publicado: (2023)

Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?
por: Ağaç, Mustafa Tarık, et al.
Publicado: (2019)

Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients
por: Akyurek, Fikret, et al.
Publicado: (2021)

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
por: Hwang, You-Cheol, et al.
Publicado: (2019)

The Relationship of Serum Trimethylamine N-Oxide Levels with Carotid Intima-Media Thickness and Disease Activity in Psoriasis Patients
por: Zekey, Emre, et al.
Publicado: (2023)

Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
por: Aleem, Mudassar, et al.
Publicado: (2022)

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
por: Robinson, Jennifer G., et al.
Publicado: (2014)

Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2019)

To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia
por: Agrawal, Deepak, et al.
Publicado: (2018)

Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
por: Sohn, Tae Seo
Publicado: (2019)

Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
por: Hwang, You-Cheol
Publicado: (2019)

Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study
por: Lee, Seung-Ah, et al.
Publicado: (2023)

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years
por: Constance, Christian, et al.
Publicado: (2014)

A Bioequivalence Study of Ezetimibe/Rosuvastatin Fixed Dose Combination (10 mg/10 mg) Versus the Individual Formulations Taken Concomitantly
por: Di, Yujing, et al.
Publicado: (2023)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

The relation between neutrophil-to-lymphocyte ratio and coronary chronic total occlusions
por: Demir, Kenan, et al.
Publicado: (2014)

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
por: Viigimaa, Margus, et al.
Publicado: (2010)

Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects
por: Hwang, Inyoung, et al.
Publicado: (2018)

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years
por: Ben-Yehuda, Ori, et al.
Publicado: (2011)

In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin
por: Galani, VJ, et al.
Publicado: (2010)

Rosuvastatin exerts cardioprotective effect in lipopolysaccharide-mediated injury of cardiomyocytes in an MG53-dependent manner
por: Zhuang, Jiawei, et al.
Publicado: (2022)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
por: Masadeh, Majed, et al.
Publicado: (2012)

Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
por: Christou, Theodore, et al.
Publicado: (2014)

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia
por: Vahit, Demir, et al.
Publicado: (2018)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
por: Perez-Calahorra, Sofía, et al.
Publicado: (2019)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2019)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome
por: Umrani, Salman, et al.
Publicado: (2020)

Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
por: Abbas, Ahmed, et al.
Publicado: (2012)

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients
por: Barakat, Lolwa, et al.
Publicado: (2013)

Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
por: Khurana, Sushant, et al.
Publicado: (2015)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome
por: Kumar, Besham, et al.
Publicado: (2019)

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
por: Han, Eugene, et al.
Publicado: (2017)

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants
por: Anderson, Kacey, et al.
Publicado: (2021)

Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels
por: Engin-Üstün, Yaprak, et al.
Publicado: (2016)

Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk
por: Cho, Yun-Kyeong, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_td0mc42gpfcu29uq02a46s34b4